Consent given pursuant to sections 14 and 14A for the supply and importation of the Therapeutic Goods specified subject to conditions specified - between 18 September 2012 and 24 December 2012

Administered by Department of Health, Disability and Ageing

Legislation au C2013G00077 In force Gazette

Legislation content

 

Section 14 and 14a Notice

R12/ 1048892

Between 18th September 2012 and 24th December 2012, the delegate of the Secretary of the Department of Health and Ageing gave consent pursuant to sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) to the following:

  1. The supply, importation of the therapeutic goods or classes of therapeutic goods specified in Column 2 of the Table and with the Australian Register of Therapeutic Goods number (ARTG No.) specified in Column 3 of the Table; and
  2. Without conforming to those clauses, specified in Column 5 of the Table, of the standard, specified in the Column 4 of the Table otherwise applicable to the goods.

 

Pursuant to section 15(1) of the Act, consent is subject to the conditions specified in Column 6 of the Table and consent is given for the period specified in Column 7 of the Table, provided all other requirements of the standard are met.

 

Column 1

Column 2

Column 3

Column 4

Column5

Column 6

Column 7

Sponsor

Goods or Classes of Goods

ARTG No.

Standard

Clause

Conditions

Period for which consent is given

Pfizer Australia Pty Ltd

Centrum for Men

200421

TGO 78

10(b)

The upper limit for the contents of lutein and lycopene in the tablets can increase from 120% to 165.0% of the stated content.

Until further notice

Centrum for Women

200414

Health World Limited

Metagenics Estrofactors

197988

TGO 78

10(b)

The upper limit of 150% for calcium folinate as specified in TGO 78 can be exceeded in one packaged batch made from bulk batch 15291

Applicable to Batch 15291 only.

Sanofi-Aventis Healthcare Pty Ltd T/A Sanofi-Aventis Consumer Healthcare

Cenovis Men’s Multi Performance

202158

TGO 69

3(2)(g)

Product label does not include the Required Advisory Statements for Medicine Labels (RASML) statements 32 and 33:

  • ‘WARNING – When taken in excess of 3000 micrograms retinol equivalents, vitamin A can cause birth defects.’
  • ‘If you are pregnant, or considering becoming pregnant, do not take vitamin A supplements without consulting your doctor or pharmacist.’

Label that includes the following abridged version of RASML statement 31:

  • ‘The recommended daily amount of vitamin A from all sources is 900 micrograms retinol equivalents for men.’

Until further notice.

Pharmacare Laboratories Pty Ltd

Nature’s Way High Strength Olive Leaf 6000mg

192703

TGO 78

 

The upper limit of 120% for oleuropein can be waived.

Applicable to packaged batch made from bulk batch 15659 of capsules.

Nestle Australia Ltd

Anticol Extra Strong

203083

TGO 69

3(12)(a)

The individual unsealed wrapper around each lozenge is not required to include the product name, the names of all the active ingredients and their quantities, provided the individual wrappers include the name of sponsor, and the outer label of the pack complies fully with TGO 69

Until further notice

Bausch & Lomb Australia Pty Ltd

Ocuvite Lutein capsules

200282

TGO 78

 

Adopt limits of 90.0 – 150.0% for the content of lutein in each capsule.

Until further notice.

 

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.